Orchard Therapeutics Plc (NASDAQ:ORTX) reported Q4 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $300 thousand.
For earnings history and earnings-related data on Orchard Therapeutics Plc click here.